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Abstract
Background—US guidelines now recommend that all HIV-infected persons receive 
antiretroviral therapy). HIV prevention is increasingly focused on ensuring that infected persons 
are diagnosed soon after HIV acquisition and quickly link to care and initiate antiretroviral 
therapy. We examined trends in time from HIV diagnosis to viral load suppression in King County, 
WA, to gauge improvement in our HIV care continuum over time.
Methods—We used HIV surveillance data and Cox proportional hazards to evaluate how the 
time from diagnosis to viral suppression changed among persons newly diagnosed as having HIV 
in King County, WA, between 2007 and 2013.
Results—A total of 1490 (84%) of 1766 newly diagnosed persons achieved viral suppression in a 
median time of 213 days (95% confidence interval, 203–229). Thirty-six percent of all persons 
diagnosed in 2007 and 77% in 2013 were virally suppressed within 12 months of HIV diagnosis 
(P < 0.0001). Differences in time to suppression by calendar year persisted when stratifying by 
CD4 count at diagnosis. Race was not significantly associated with time to viral suppression.
Conclusions—Time from HIV diagnosis to viral suppression dramatically declined between 
2007 and 2013, and more than three quarters of recently HIV-diagnosed individuals in King 
County, WA, now achieve viral suppression within a year of diagnosis. This improvement was 
evident among all persons newly diagnosed as having HIV, regardless of race/ethnicity or CD4 
count at time of diagnosis.
In 2012, US Health Resources and Service Administration recommended that all persons 
with human immunodeficiency virus (HIV) infection receive antiretroviral treatment (ART), 
regardless of their CD4 lymphocyte count (Table 1).5 That change in treatment guidelines 
was adopted in the face of new evidence that early ART improves patients’ health and has 
the potential to diminish HIV transmission.6,7 The emphasis on early treatment codified in 
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the guidelines is also evident in the US National HIV/AIDS Strategy, and the more recent 
HIV Care Continuum Initiative.8 All of these documents focus on the HIV care continuum
—the sequential steps from HIV diagnosis, to linkage and retention in care, ART initiation, 
and viral suppression9–12—and all emphasize the importance of identifying persons with 
HIV infection shortly after HIV acquisition and rapidly achieving the goal of viral 
suppression.
We previously published data on the HIV care continuum in King County, WA, 
demonstrating that 67% to 75% of all diagnosed persons with HIV infection are virally 
suppressed.13,14 This cross-sectional evaluation is a measure of the success of the HIV 
prevention and care system in King County, but provides relatively little insight into the 
system’s success in meeting the needs of persons with recently diagnosed HIV infection, 
and accelerating progress along the HIV care continuum. Here we present data on trends in 
the time from diagnosis to viral suppression among persons diagnosed as having HIV 
infection in King County, WA, from 2007 to 2013, demonstrating that our local care system 
has rapidly responded to new scientific evidence, treatment guidelines, and public health 
initiatives that emphasize early linkage to care and initiation of ART.
MATERIALS AND METHODS
We examined the time from HIV diagnosis to viral suppression among persons diagnosed as 
having HIV infection in King County, WA, from 2007 to 2013. The work was conducted at 
the Public Health–Seattle & King County HIV/AIDS Epidemiology section and included the 
period after all CD4 and viral loads became legally reportable (mid-2006). Participants 
included all HIV-infected individuals older than 14 years diagnosed between 2007 and 2013 
who resided in King County at the time of diagnosis and were reported to Public Health–
Seattle & King County as of June 4, 2015. Individuals known to be enrolled in research 
studies were not included in this analysis because WA State law excludes research studies 
from HIV laboratory reporting requirements. Study status is ascertained through provider 
and patient contact either during surveillance and partner services investigations undertaken 
when cases are first reported or, if the individual has not had a laboratory in a 12-month 
period, through an investigation undertaken of persons thought to be out of care. Public 
Health does not collect data on the period of study involvement, so we excluded individuals 
enrolled in a study at any point.
This study is a secondary data analysis of data collected through public health HIV 
surveillance, including HIV Incidence and Core HIV Surveillance data sources. HIV 
Incidence and Core HIV Surveillance comprise the Washington State HIV data system 
called eHARS. HIV Incidence collects testing data, whereas Core contains demographic and 
transmission characteristics and laboratory tests. Both sources contain data from medical 
record abstractions, provider reports, and patient interviews. HIV core surveillance and 
partner services investigations are substantially integrated in King County, and Public Health 
attempts to interview all persons with newly diagnosed HIV infection. We defined first HIV 
diagnosis as the earliest positive HIV diagnostic test result or date of self-reported HIV 
diagnosis. In the event that these differed by more than 40 days, Public Health staff 
investigated cases to establish which date was likely to be the more accurate. The date of 
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initial viral suppression was defined as the date of first reported plasma quantitative real-
time HIV-1 RNA polymerase chain reaction test result showing an HIV viral load of 200 
copies/mL or less. This assay is consistently used for viral load quantification in King 
County. The following variables were assessed for associations with time to viral 
suppression: age group at time of diagnosis (15–24, 25–34, 35–44, 45–54, 55+ years), sex, 
race/ethnicity (non-Hispanic white, foreign-born black, non-Hispanic US born black, 
Hispanic, and other), HIV exposure category (men who have sex with men [MSM], injection 
drug user [IDU], MSM-IDU, unknown exposure, or heterosexual exposure as indicated by 
the National HIV Surveillance System), CD4 lymphocyte count within the first 6 months of 
diagnosis (defined in groups <350, 350–500, >500 per mm3), and year of diagnosis (2007 
through 2013). CD4 counts more than 6 months after diagnosis were changed to missing due 
to concern that such values might not be representative of CD4 counts at time of diagnosis.
We calculated estimates of time taken for 50% and 75% of the population to reach viral 
suppression and created Kaplan-Meier survival plots to visually present time from HIV 
diagnosis to viral suppression. Individuals contributed time from their date of HIV diagnosis 
to the date of initial viral suppression (event). Persons with no laboratory results 
demonstrating HIV viral suppression who were not known to have left the area or died were 
censored on the date the analytic dataset was created (June 5, 2015). Persons who died were 
censored on the date of their death. Patient deaths are updated in eHARS from the 
Washington state and King County death certificates, the National Death Index, and the 
Social Security Death Master File. Persons who migrated out of WA State were censored on 
the date of their last laboratory test result reported to Public Heath HIV surveillance. We 
have previously reported our procedures for identifying persons who migrate out of the 
area.15 We used log rank testing and Cox proportional hazard regression to evaluate the 
association of independent variables with time to viral suppression. We decide a priori to 
include age, sex, exposure category, race/ethnicity, CD4 count at diagnosis, and year of 
diagnosis in the multivariable model of the association of independent variables with time to 
viral suppression. To address the lack of laboratory completeness validation 2007–2009, we 
repeated analysis for the 3 years with greater than 90% laboratory completeness (2011–
2013). We also conducted a secondary multivariable analysis excluding elite controllers 
(viral loads <50 copies/mL) to examine whether they were skewing results. People missing a 
CD4 count or with CD4 counts more than 6 month after diagnosis were removed from 
multivariable models. A secondary multivariable analysis and Kaplan-Meier plots were done 
for those without CD4 counts within 6 months of diagnosis and for alternative groupings of 
CD4 counts (0–200, 200–350, 350, 500, >500 per mm3).
RESULTS
Between 2007 and 2013, 1841 persons were newly diagnosed as having HIV infection in 
King County, WA. We excluded 56 persons who were enrolled in research studies and 19 
persons younger than 14 years from further analysis, leaving a study population of 1766 
persons (96% of persons newly diagnosed as having HIV during the study period). A total of 
140 (8%) people did not have a CD4 lymphocyte count reported to Public Health in the first 
6 months after HIV diagnoses; these persons were excluded from analyses that included 
CD4 count as an independent variable.
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The population was predominantly non-Hispanic white (59%), 25 to 44 years of age (59%), 
and composed of MSM (76% including 8% MSM-IDU; Table 2). Of those with CD4 
lymphocyte counts done within 6 months of diagnosis, 45% had less than 350 cells/mm3. 
Although some demographic, clinical, and risk characteristics varied year-to-year, we did 
not observe significant changes in trends of the characteristics of the newly HIV-diagnosed 
population.
The 1766 newly diagnosed persons included in the study population achieved viral 
suppression or were censored in a median time of 258 days (0–3063 days) with an average 
of 3 viral loads per year before suppression. Of the 276 (16%) who were censored without 
achieving viral suppression, 36 (13%) died, 86 (31%) moved out of the state, 56 (20%) were 
still in care with laboratory results reported to surveillance in the final year of study 
observation (June 2014 or later), and 98 (36%) had no laboratory test results reported in 
surveillance in the final year of study observation and were not known to have moved out of 
state or died. This indicates roughly 9% (154 persons) of our initial population never 
achieved viral suppression, including those who seemed to be out of care as of June 2015 
(i.e., no laboratory results reported in the 12 months before the end of observation).
A total of 1490 (84%) persons achieved viral suppression in a median time of 213 days 
(95% confidence interval [CI], 203–229) after HIV diagnosis. In 2007, half of newly 
diagnosed persons had achieved viral suppression by 685 days after diagnosis. In contrast, 
by 2013, half of all newly diagnosed persons were virally suppressed 142 days after 
diagnosis. In 2007, 36% of all persons diagnosed were virally suppressed within the first 12 
months after HIV diagnosis, whereas in 2013, 77% were suppressed 12 months after HIV 
diagnosis (P < 0.0001).
Trends in time from HIV diagnosis to viral suppression varied by initial CD4 lymphocyte 
count, although all groups did see a significant decrease in time to suppression over this 
period (Fig. 1A–C [also see Figure, Supplemental Digital Content 1, http://
links.lww.com/OLQ/A120, trends for those with CD4 count 200–350 cells/mm3]). A similar 
pattern persisted when looking at those without CD4 counts within 6 months, although 
significance was lost due to small number size (see Figure, Supplemental Digital Content 2, 
http://links.lww.com/OLQ/A121, trends for those without CD4 counts). Persons with initial 
CD4 counts less than 350 cells/mm3 rapidly achieved viral suppression throughout the 
period of observation (median, 157 days; 95% CI, 151–167). Among persons with CD4 
counts greater than 500, the time from diagnosis to when 50% of persons were virally 
suppressed decreased 87%, from 1112 days in 2007 to 142 days in 2013. This decrease was 
only slightly smaller (83%) among persons with initial CD4 lymphocyte counts of 350 to 
500 cells/mm3 (717 days in 2007 vs. 120 days in 2013).
On univariate analysis, more rapid viral suppression was significantly associated with 
unknown HIV risk, IDU, or heterosexual transmission categories, female sex, CD4 
lymphocyte count less than 500 cells/mm3, older age, being a foreign-born black, and later 
year of HIV diagnosis (Table 3 and Fig. 2). On multivariable analysis, lower CD4 count, 
older age, female sex, and more recent year of diagnosis were all significantly associated 
with more rapid viral suppression (Table 4 [also see Table, Supplemental Digital Content 3, 
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http://links.lww.com/OLQ/A122, multivariable analysis with alternative CD4 groupings]). 
Similar associations were seen when restricting the analysis to those without CD4 counts at 
diagnosis (see Table, Supplemental Digital Content 4, http://links.lww.com/OLQ/A123, 
multivariate analysis for those without CD4 counts). Multivariable analysis restricted to 
2011, 2012, and 2013 showed minimal differences in variables associated with time to viral 
suppression (see Table, Supplemental Digital Content 5, http://links.lww.com/OLQ/A124, 
multivariable analysis restricted to 2011–2013). An analysis excluding 19 elite controllers 
with viral loads less than 50 copies/mL did not significantly change the multivariable 
adjusted hazard ratio (HRadj) findings (data not shown).
DISCUSSION
Evaluating King County, WA, HIV surveillance data, we found that the median time from 
diagnosis to viral load suppression declined 79% for individuals diagnosed between 2007 
and 2013, and the decline was most pronounced among persons diagnosed as having higher 
CD4 counts. We observed no significant indication of racial disparities in time to 
suppression. These findings highlight the success of one US urban area in instituting early 
initiation of ART. Further studies are needed to elucidate whether provider prescribing 
practices or other local implementation factors (funding, political climate, patient awareness, 
access to medication and the health care system, etc) are primarily responsible for early ART 
initiation. Our findings have favorable implications related to the clinical outcomes among 
persons living with HIV/AIDS and HIV transmission.16
Although much of the change in time to viral suppression is likely a consequence of changes 
in clinical practice prompted by changes in US national ART guidelines, our findings 
suggest that guideline changes alone do not entirely explain the dramatic increase in how 
quickly patients became virally suppressed. Stratifying by CD4 count, we found that the 
time to viral suppression among persons with the highest CD4 counts clearly declined before 
the 2012 change in HIV treatment guidelines recommending that all persons with HIV 
receive ART. This finding demonstrates that clinical practice favoring earlier initiation of 
ART, at least in King County, WA, changed well in advance of national treatment guidelines.
Prior studies from San Francisco and New York City (NYC) evaluated trends in time from 
diagnosis to viral load suppression. Investigators in San Francisco found that the median 
time to virologic suppression decreased roughly 69% between 2004 and 2009, from 32 
months (~960 days) to 10 months (~300 days).17 In NYC, persons suppressed (defined as 
viral load <400 copies/mL) 12 months after diagnoses increased from 36% in 2006 to 45% 
in 2009, with the most rapid viral suppression occurring among persons with the lowest CD4 
lymphocyte counts (0–199 cells/mm3).18 The pattern of viral suppression in King County in 
2009 was very similar to that reported in NYC and San Francisco; in 2009, the median time 
to viral suppression in King County was 363 days, and 50% of persons suppressed within 
the first 12 months after diagnosis. Our more recent data demonstrate that viral suppression 
now occurs much more quickly after HIV diagnosis. That older data from King County are 
so similar to findings in other cities suggests that our more recent data may be reflective of 
patterns of viral suppression occurring in at least some other US cities.
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After adjusting for calendar year and CD4 count at time of HIV diagnosis, the only factor 
significantly associated with a lower likelihood of viral suppression was younger age. This 
finding highlights the need to focus particular attention on young persons with HIV, but also 
demonstrates our area’s success in avoiding significant racial or ethnic disparities in 
ensuring that persons with HIV receive the care they need after HIV diagnosis. Nationally, 
blacks are less likely to be virally suppressed than whites, and reducing HIV-related 
disparities is a critical component of the National HIV/AIDS Strategy.19,20 Our findings are 
good evidence that such disparities can be mitigated, at least in the initial period after HIV 
diagnosis.
Our study has several limitations. Laboratory reporting improved over the study period, and 
more complete ascertainment of viral suppression, rather than a true change in virologic 
outcomes, may have contributed to our findings. Although this change in surveillance data 
quality could have affected data from earlier years of observation, we believe that changes in 
data completeness are unlikely to have affected our more recent data. Viral load reporting 
completeness increased from 86% in 2010 to 93% in 2011 and has subsequently stayed 
high.21 Because of an administrative censoring date of June 5, 2015, it is also possible that 
very recent laboratories were missed, although this impact should be small due to high levels 
of suppression before this date. Surveillance data could also be limited by missing or 
inaccurate dates of HIV diagnosis. However, all new HIV diagnoses in King County are 
investigated through medical record reviews and, when possible, interviews with patients 
conducted as part of HIV partner services, and date of HIV diagnosis reflects the results of 
these comprehensive efforts. We may also be unaware of individuals enrolled in studies, 
although through initial interviews and follow-up with providers when laboratories are 
missing, missing study information should be minimized. Our team would not have 
ascertained viral suppression among persons who left WA State after HIV diagnosis. When 
looking at the total population of persons living with HIV/AIDS, migration leads to 
substantial underestimates of population-level viral suppression.11 This limitation is likely 
less important when evaluating outcomes in the period immediately after HIV diagnosis, but 
could have led to an underestimate of viral suppression in our data. We defined time to viral 
suppression using the date of first HIV RNA test demonstrating viral suppression. The true 
time to viral suppression is clearly somewhat shorter than this date. Thus, our findings are 
conservative. Finally, because it was not possible to include specific drug regimen used as an 
independent variable in our analysis, we cannot assess the extent to which more rapid viral 
suppression may have been a consequence of use of drug regimens that more quickly 
achieve viral suppression.
In summary, we found that the time from HIV diagnosis to viral suppression dramatically 
declined between 2007 and 2013; that the median time from diagnosis to documented viral 
suppression in King County, WA, in 2013 was 142 days; and that 77% persons in the area in 
2013 were virally suppressed within 1 year of HIV diagnosis. Although additional efforts to 
further shorten this period between diagnosis and effective treatment may be worthwhile, 
our findings demonstrate that most persons with HIV in our area rapidly achieve the goals of 
HIV treatment after initial diagnosis. In areas like ours, efforts to minimize the morbidity 
associated with HIV and diminish transmission should focus on ensuring that HIV diagnoses 
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occur as quickly as possible after infection and promoting the effective treatment for the 
minority of persons who fail to achieve viral suppression.
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A–C, Kaplan-Meier curves depicting time to viral load suppression by diagnosis year, 
among those with CD4 counts less than 350 cells/mm3, 350–500 cells/mm3, and greater than 
500 cells/mm3 in King County, WA (2007–2013).
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A–F, Kaplan-Meier curves depicting time to viral load suppression among newly diagnosed 
cases by age, sex, year of diagnosis, CD4 count, race/ethnicity, and transmission category in 
King County, WA (2007–2013). HETERO indicates heterosexuals.
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TABLE 1
ART Initiation Recommendation Issued by “Department of Health & Human Services” (2006–2012)1–4
2006 After CD4 count <350/mm3 and before 200/mm3
2008 Before CD4 count <350/mm3 with individualized initiation decisions >350/mm3
2009 CD4 count ≤500/mm3
2012 ART to all patients regardless of CD4 count
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TABLE 4
Multivariable Proportional Cox Analysis of Variables Associated With Viral Suppression After HIV Diagnosis 
in King County, WA (2007–2013)
HRadj 95% CI P
Race/ethnicity
 Foreign-born black 1.05 0.82–1.33   0.72
 US-born black 0.87 0.72–1.06   0.17
 Hispanic 0.96 0.82–1.12   0.60
 Other 0.97 0.81–1.17   0.77
 Non-Hispanic white Reference
CD4, cells/mm3
 <350 2.07 1.82–2.35 <0.0001
 350–500 1.27 1.10–1.47 <0.01
 >500 Reference
Sex
 Female 1.31 1.02–1.69   0.04
 Male Reference
Age at diagnosis, y
 15–24 0.80 0.63–1.01   0.06
 25–34 0.79 0.64–0.98   0.03
 35–44 0.93 0.75–1.15   0.48
 45–54 1.09 0.87–1.36   0.48
 55+ Reference
Risk
 Unknown 1.05 0.80–1.37   0.73
 IDU 0.75 0.53–1.08   0.12
 MSM 1.03 0.78–1.36   0.81
 MSM/IDU 0.72 0.52–1.01   0.06
 Heterosexual Reference
Year of diagnosis
 2007 0.39 0.32–0.48 <0.0001
 2008 0.43 0.35–0.52 <0.0001
 2009 0.49 0.39–0.60 <0.0001
 2010 0.58 0.47–0.70 <0.0001
 2011 0.71 0.58–0.87 <0.01
 2012 0.70 0.57–0.86 <0.001
 2013 Reference
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